M. Gervin

2.7k total citations · 1 hit paper
35 papers, 2.1k citations indexed

About

M. Gervin is a scholar working on Psychiatry and Mental health, Clinical Psychology and Social Psychology. According to data from OpenAlex, M. Gervin has authored 35 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Psychiatry and Mental health, 12 papers in Clinical Psychology and 11 papers in Social Psychology. Recurrent topics in M. Gervin's work include Schizophrenia research and treatment (25 papers), Mental Health Treatment and Access (11 papers) and Mental Health and Psychiatry (10 papers). M. Gervin is often cited by papers focused on Schizophrenia research and treatment (25 papers), Mental Health Treatment and Access (11 papers) and Mental Health and Psychiatry (10 papers). M. Gervin collaborates with scholars based in Ireland, United States and Australia. M. Gervin's co-authors include Mary Clarke, S. Browne, Stephen Browne, Eadbhard O’Callaghan, Abbie Lane, E. O’Callaghan, C. Larkin, A. Kinsella, Conall Larkin and Mark J. Roe and has published in prestigious journals such as American Journal of Psychiatry, The British Journal of Psychiatry and Psychological Medicine.

In The Last Decade

M. Gervin

31 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia

2003 511 citations Josep María Haro, Susana Ochoa et al. Acta Psychiatrica Scandinavica profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Gervin Ireland	19	1.8k	768	614	393	235	35	2.1k
C. J. Slooff Netherlands	25	1.7k 1.0×	706 0.9×	562 0.9×	359 0.9×	254 1.1×	69	2.2k
Andreas Marneros Germany	30	2.1k 1.2×	1.2k 1.5×	732 1.2×	245 0.6×	305 1.3×	145	2.9k
Fokko Nienhuis Netherlands	22	1.8k 1.0×	856 1.1×	780 1.3×	423 1.1×	304 1.3×	45	2.2k
Piet Oosthuizen South Africa	24	1.0k 0.6×	800 1.0×	267 0.4×	226 0.6×	240 1.0×	39	1.7k
L Brambilla Italy	4	1.5k 0.8×	676 0.9×	419 0.7×	273 0.7×	354 1.5×	8	1.8k
Stephen Geisler United States	6	1.4k 0.8×	541 0.7×	513 0.8×	160 0.4×	116 0.5×	7	1.5k
Laila Asmal South Africa	23	1.2k 0.7×	491 0.6×	315 0.5×	224 0.6×	135 0.6×	87	1.7k
Roger Smyth United Kingdom	12	972 0.5×	591 0.8×	444 0.7×	181 0.5×	129 0.5×	15	1.4k
Martin Hambrecht Germany	20	2.1k 1.2×	919 1.2×	827 1.3×	460 1.2×	376 1.6×	44	2.7k
Barbara C. Walsh United States	12	1.0k 0.6×	416 0.5×	407 0.7×	202 0.5×	183 0.8×	18	1.3k

Countries citing papers authored by M. Gervin

Since Specialization

Citations

This map shows the geographic impact of M. Gervin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Gervin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Gervin more than expected).

Fields of papers citing papers by M. Gervin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Gervin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Gervin. The network helps show where M. Gervin may publish in the future.

Co-authorship network of co-authors of M. Gervin

This figure shows the co-authorship network connecting the top 25 collaborators of M. Gervin. A scholar is included among the top collaborators of M. Gervin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Gervin. M. Gervin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gervin, M., et al.. (2018). Autistic spectrum disorder without intellectual impairment in adult mental health services – fostering new perspectives and enhancing existing services. Irish Journal of Psychological Medicine. 39(3). 312–318. 6 indexed citations

Hill, Michele, Niall Crumlish, Peter Whitty, et al.. (2011). The relationship between insight and neurological dysfunction in first-episode psychosis. European Psychiatry. 27(3). 200–205. 5 indexed citations

Kamali, Moayyad, Orfhlaith McTigue, Peter Whitty, et al.. (2009). Lifetime history of substance misuse in first‐episode psychosis: prevalence and its influence on psychopathology and onset of psychotic symptoms. Early Intervention in Psychiatry. 3(3). 198–203. 12 indexed citations

Crumlish, Niall, Peter Whitty, Mary Clarke, et al.. (2008). Beyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosis. The British Journal of Psychiatry. 194(1). 18–24. 158 indexed citations

Clarke, Mary, Stephen Browne, Orfhlaith McTigue, et al.. (2007). Determinants of duration of untreated psychosis in an Irish catchment area sample. Irish Journal of Psychological Medicine. 24(2). 50–54. 5 indexed citations

Clarke, Mary, Peter Whitty, Stephen Browne, et al.. (2006). Untreated illness and outcome of psychosis. The British Journal of Psychiatry. 189(3). 235–240. 83 indexed citations

Whitty, Peter, Mary Clarke, Orfhlaith McTigue, et al.. (2006). Diagnostic specificity and predictors of neurological soft signs in schizophrenia, bipolar disorder and other psychoses over the first 4 years of illness. Schizophrenia Research. 86(1-3). 110–117. 63 indexed citations

Kamali, M., Brendan D. Kelly, Mary Clarke, et al.. (2006). A prospective evaluation of adherence to medication in first episode schizophrenia. European Psychiatry. 21(1). 29–33. 97 indexed citations

Foley, Sharon, Brendan D. Kelly, Mary Clarke, et al.. (2004). Incidence and clinical correlates of aggression and violence at presentation in patients with first episode psychosis. Schizophrenia Research. 72(2-3). 161–168. 108 indexed citations

10.

Kelly, Brendan D., Mary Clarke, S. Browne, et al.. (2004). Clinical predictors of admission status in first episode schizophrenia. European Psychiatry. 19(2). 67–71. 62 indexed citations

11.

Haro, Josep María, Susana Ochoa, Diego Novick, et al.. (2003). The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatrica Scandinavica. 107(s416). 16–23. 511 indexed citations breakdown →

12.

Gervin, M., et al.. (2001). Heroin smoking by “chasing the dragon” in young opiate users in Ireland: stability and associations with use to “come down” off “Ecstasy”. Journal of Substance Abuse Treatment. 20(4). 297–300. 18 indexed citations

13.

Browne, S., Mary Clarke, M. Gervin, et al.. (2000). Determinants of neurological dysfunction in first episode schizophrenia. Psychological Medicine. 30(6). 1433–1441. 91 indexed citations

14.

Kamali, M., et al.. (2000). The prevalence of comorbid substance misuse and its influence on suicidal ideation among in‐patients with schizophrenia. Acta Psychiatrica Scandinavica. 101(6). 452–456. 81 indexed citations

15.

Gervin, M., et al.. (1999). Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology. European Psychiatry. 14(7). 405–409. 22 indexed citations

16.

Browne, Stephen, et al.. (1998). Quality of Life in Schizophrenia: Insight and Subjective Response to Neuroleptics. The Journal of Nervous and Mental Disease. 186(2). 74–78. 69 indexed citations

17.

Gervin, M., Stephen Browne, Abbie Lane, et al.. (1998). Spontaneous Abnormal Involuntary Movements in First-Episode Schizophrenia and Schizophreniform Disorder: Baseline Rate in a Group of Patients From an Irish Catchment Area. American Journal of Psychiatry. 155(9). 1202–1206. 54 indexed citations

18.

Browne, S., et al.. (1998). Soft signs in first episode schizophrenia: Evidence for trait and state processes influencing neurological performance. Schizophrenia Research. 29(1-2). 180–180. 1 indexed citations

19.

Browne, S., Mark J. Roe, Abbie Lane, et al.. (1996). Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatrica Scandinavica. 94(2). 118–124. 277 indexed citations

20.

Browne, S., Mark J. Roe, Abbie Lane, et al.. (1996). A preliminary report on the effect of a psychosocial and educative rehabilitation programme on quality of life and symptomatology in schizophrenia. European Psychiatry. 11(8). 386–389. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact